PET of hypoxia with89Zr-labeled cG250-F(ab')2 in head and neck tumors

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1076-1083

  Hoeben, Bianca A W ^a   Kaanders, Johannes H A M ^a   Franssen, Gerben M ^a   Troost, Esther G C ^a   Rijken, Paul F J W ^a   Oosterwijk, Egbert ^a   Van Dongen, Guus A M S ^b   Oyen, Wim J G ^a   Boerman, Otto C ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

CAIX; CG250 F(ab')2; Head and neck carcinoma; Hypoxia; Small animal PET

Indexed keywords

CARBONATE DEHYDRATASE IX; HOE 33342; PIMONIDAZOLE; CARBONATE DEHYDRATASE INHIBITOR; DIAGNOSTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; NITROIMIDAZOLE DERIVATIVE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BAGG ALBINO MOUSE; CANCER SURGERY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HYPOXIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; TUMOR XENOGRAFT; ANIMAL; ANOXIA; DRUG SCREENING; HEAD AND NECK TUMOR; IMAGE PROCESSING; IMMUNOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; ANOXIA; ANTIBODIES, MONOCLONAL; AUTORADIOGRAPHY; CARBONIC ANHYDRASE INHIBITORS; HEAD AND NECK NEOPLASMS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; NITROIMIDAZOLES; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZIRCONIUM;

EID: 77955001665     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.073189     Document Type: Article

References (40)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-276.
2. Rademakers SE, Span PN, Kaanders JH, Sweep FC, van der Kogel AJ, Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol. 2008;2:41-53.
3. Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics. 1996;33:480-487.
4. Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem. 2006;42:167-216.
5. Gatenby RA, Gawlinski ET. A reaction-diffusion model of cancer invasion. Cancer Res. 1996;56:5745-5753.
6. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075-7083.
7. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489-494.
8. Ahlskog JK, Schliemann C, Marlind J, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer. 2009;101:645-657.
9. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 2000;85:865-870.
10. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304-310.
11. Kaanders JH, Bussink J, van der Kogel AJ. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol. 2004;14:233-240.
12. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112-117.
13. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861-2871.
14. Troost EG, Bussink J, Kaanders JH, et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol. 2005;76:194-199.
15. Massuger LF, Boerman OC, Corstens FH, et al. Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F (ab9) 2 fragments in tumor-bearing athymic mice. Anticancer Res. 1991;11:2051-2057.
16. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F (ab9) 2, and Fab9 in mice. Cancer Res. 1986;46:3969-3978.
17. 131I-labeled F (ab') 2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Cancer Biother Radiopharm. 2004;19:466-477.
18. 89Zrlabeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
19. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
20. Visser EP, Disselhorst JA, Brom M, et al. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med. 2009;50:139-147.
21. Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA, van der Kogel AJ. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys. 2000;48:571-582.
22. Thevenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process. 1998;7:27-41.
23. Jonathan RA, Wijffels KI, Peeters W, et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol. 2006;79:288-297.
24. Airley RE, Loncaster J, Raleigh JA, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer. 2003;104:85-91.
25. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 2002;62:7066-7074.
26. Hoogsteen IJ, Lok J, Marres HA, et al. Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia. Eur J Cancer. 2009;45:2906-2914.
27. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 2006;24:727-735.
28. Span PN, Bussink J, Manders P, Beex LV, Sweep CG. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer. 2003;89:271-276.
29. Ljungkvist AS, Bussink J, Kaanders JH, et al. Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys. 2005;62:1157-1168.
30. Bussink J, Kaanders JH, Strik AM, Vojnovic B, van der Kogel AJ. Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines. Radiat Res. 2000;154:547-555.
31. 4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493-1502.
32. van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renalcell carcinoma xenografts: relative effects of size and affinity. Int J Cancer. 1991;48:738-743.
33. Khawli LA, Alauddin MM, Hu P, Epstein AL. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F (ab') 2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm. 2003;18:931-940.
34. 124I-cG250 PET/CT. Urol Oncol. June 11, 2009 [Epub ahead of print].
35. 18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol. 2006;80:157-164.
36. Busk M, Horsman MR, Jakobsen S, et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys. 2008;70:1202-1212.
37. Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol. 2006;33:743-750.
38. 4-methylthiosemicarbazone). J Nucl Med. 2006;47:989-998.
39. Perk LR, Vosjan MJ, Visser GW, et al. p-Isothiocyanatobenzyl- desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010;37:250-259.
40. Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors: design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem. 2005;48:4834-4841.